Amnesia induced by β-amyloid fragments is counteracted by cannabinoid CB1 receptor blockade

European Journal of Pharmacology

Volumn 477, Issue 3, 2003, Pages 219-225

  Mazzola, Carmen ^a   Micale, Vincenzo ^a   Drago, Filippo ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Amyloid fragment; Amnesia; Avoidance retention; Cannabinoid; Cannabinoid CB1 receptor

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN[25-35]; RIMONABANT;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENCY; LEARNING; MALE; MEMORY CONSOLIDATION; MEMORY DISORDER; MOUSE; NONHUMAN; PASSIVE AVOIDANCE; PRIORITY JOURNAL; TASK PERFORMANCE; TRANSIENT GLOBAL AMNESIA;

AMNESIA; AMYLOID BETA-PROTEIN; ANIMALS; AVOIDANCE LEARNING; DRUG ADMINISTRATION SCHEDULE; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENTRICULAR; MALE; MICE; PEPTIDE FRAGMENTS; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RETENTION (PSYCHOLOGY); TIME FACTORS;

EID: 1642320366     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2003.08.026     Document Type: Article

References (54)

1. Aigner T.G. Pharmacology of memory: cholinergic-glutamatergic interactions. Curr. Opin. Neurobiol. 5:1995;155-160.
2. Behl C. Alzheimer's disease and oxidative stress: implication for novel therapeutic approaches. Prog. Neurobiol. 57:1999;301-323.
3. Brodkin J., Moerschbaecher J.M. SR141716A antagonizes the disruptive effects of cannabinoid ligands on learning in rats. J. Pharmacol. Exp. Ther. 282:1997;1526-1532.
4. 9-tetrahydrocannabinol in rats. Brain Res. 809:1998;1-4.
5. Chait L.D., Perry J.L. Acute and residual effects of alcohol and marijuana, alone and in combination, on mood and performance. Psycopharmacology. 115:1994;340-349.
6. Chen G., Chen K., Knox J., Inglis J., Bernard A., Martin S.J., Justice A., McConlogue L., Games D., Freedman S.B., Morris R.G.M. A learning deficit related to age and β-amyloid plaques in a mouse model of Alzheimer's disease. Nature. 408:2000;975-979.
7. Clemens J.A., Stephenson D.T. Implants containing beta-amyloid protein are not neurotoxic to young and old rat brain. Neurobiol. Aging. 13:1992;581-586.
8. Curcio C.A., Kemper T. Nucleus raphe dorsalis in the dementia of the Alzheimer-type: neurofibrillary changes and neuronal packing density. J. Neuropathol. Exp. Neurol. 43:1984;359-368.
9. De Wied D. From stress hormones to neuropeptides. Burbach J.P.H., De Wied D. Brain Functions of Neuropeptides. 1993;65-84 The Partenon Publishing Group, Lancs.
10. De Wied D., Joëls M., Burbach J.P.H., De Jong W., De Kloet E.R., Gaffori E.J.W., Urban I.J.A., Van Ree J.M., Van Wimersma Greidanus Tj. B., Veldhuis H.D., Versteeg D.H.G., Wiegant V.M. Vasopressin effects of the central nervous system. Negro-Villar A., Conn P.M. Peptide Hormones: Effects and Mechanisms of Action. 1988;97-140 CRC Press, Boca Raton.
11. Evans S. Effects of drug abuse on acquisition of behavioural chain in squirrel monkeys. Psycopharmacology. 107:1992;55-60.
12. Flood J.F., Morley J.E., Roberts E. An amyloid β-protein fragment, Aβ[12-28] equipotently impairs post-training memory processing when injected into different limbic structures. Brain Res. 663:1994;271-276.
13. Fukuchi K., Ho L., Younkin S.G., Kunkel D.D., Ogburn C.E., Le Bouef R.C., Furlong C.E., Deeb S.S., Nochlin D., Wegiel J., Wisniewski H.M., Martin G.M. High levels of circulating β-amyloid peptide do not cause cerebral β-amyloidosis in transgenic mice. Am. J. Pathol. 149:1996;219-227.
14. Gessa G.L., Mascia M.S., Casu M.A., Carta G. Inhibition of hippocampal acetylcholine release by cannabinoids: reversal by SR141716A. Eur. J. Pharmacol. 327:1997;R1-R2.
15. Gessa G.L., Melis M., Muntoni A.L., Diana M. Cannabinoids activate dopamine neurons by an action on cannabinoid CB1 receptors. Eur. J. Pharmacol. 341:1998;39-44.
16. Gessa G.L., Casu M.A., Carta G., Mascia M.S. Cannabinoids decrease acetylcholine release in the medial prefrontal cortex and hippocampus, reversal by SR141716A. Eur. J. Pharmacol. 355:1998;119-124.
17. Gifford A.N., Ashby C.R. Jr. Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, SR141716A. J. Pharmacol. Exp. Ther. 227:1996;1431-1436.
18. Gifford A.N., Bruneus M., Gatley S.J., Volkow N.D. Cannabinoid receptor-mediated inhibition of acetylcholine release from hippocampal and cortical synaptosomes. Br. J. Pharmacol. 131:2000;645-650.
19. Giovannelli L., Casamenti F., Scali C., Bartolini L., Pepeu G. Differential effects of amyloid peptides β-(1-40) and β-(25-35) injections into the rat nucleus basalis. Neuroscience. 66:1995;781-791.
20. Heishman S.J., Arastesh K., Stitzer M.L. Comparative effects of alcohol and marijuana on mood, memory and performance. Pharmacol. Biochem. Behav. 58:1997;93-101.
21. Herkenham M. Localization of cannabinoid receptors in brain and periphery. Pertwee R.G. Cannabinoid Receptors. 1995;145-166 Academic Press, New York, NY.
22. Heyser C.J., Hampson R.E., Deadwyler A. Effects of delta-9- tetrahydrocannabinol on delayed match to sample performance in rats: alterations in short-term memory associated with changes in task specific firing of hippocampal cells. J. Pharmacol. Exp. Ther. 264:1993;294-307.
23. Hiramatsu M., Inoue K., Kameyama T. Dynorphin A-(1-13) and (2-13) improve β-amyloid peptide-induced amnesia in mice. NeuroReport. 11:2000;431-435.
24. Hurst D.P., Lynch D.L., Barnett-Norris J., Hyatt S.M., Seltzman H.H., Zhong M., Song Z.H., Nie J., Lewis D., Reggio P.H. N-(piperidin-1-yl)-5-(4- chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor. Mol. Pharmacol. 62:2002;1274-1287.
25. Janus C., Pearson J., McLaurin J., Mathews T., Jiang Y., Schmidt S., Chishti M., Horne P., Heslin D., French J., Mount H.T.J., Nixon R.A., Mercken M., Bergeron C., Fraser P., St George-Hyslop P., Westaway D. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 408:2000;979-982.
26. Jentsch J.D., Andrusiak E., Tran A., Browers M.B., Roth R.H. Delta-9-tetrahydrocannabinol increases prefrontal cortical catecholaminergic utilization and impairs spatial working memory in the rats: blockade of dopaminergic effects with HA966. Neuropsychopharmacology. 16:1997;426-432.
27. Kowall W.N., Beal F.M., Busciglio J., Duffy K.L., Yankner B.A. An in vivo model for the neurodegenerative effects of β-amyloid and protection by substance P. Proc. Natl. Acad. Sci. U. S. A. 88:1991;7247-7251.
28. Lichtman A.H., Dimen K.R., Martin B.R. Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats. Psycopharmacology. 119:1995;282-290.
29. Lichtman A.H., Martin B.R. Delta-9-tetrahydrocannabinol impairs spatial memory through a cannabinoid receptor mechanism. Psycopharmacology. 126:1996;125-131.
30. Lyness A.S., Zarow C., Chui H.C. Neuron loss in key cholinergic and aminergic nuclei in Alzheimer disease: a meta-analysis. Neurobiol. Aging. 24:2003;1-23.
31. Mallet P.E., Beninger R.J. The cannabinoid CB1 receptor antagonist SR141716A attenuates the memory impairment produced by delta-9- tetrahydrocannabinol or anandamide. Psycopharmacology. 140:1998;11-19.
32. Maurice T., Lockart B.P., Private A. Amnesia induced by centrally administered β-amyloid peptides involves cholinergic dysfunction. Brain Res. 706:1996;181-193.
33. McGeer P.L., McGeer E.G. Inflammation of the brain in Alzheimer's disease: implications for therapy. J. Leukoc. Biol. 65:1999;409-415.
34. Miller L.L., Branconnier R.J. Cannabis: effects on memory and the cholinergic limbic system. Psychol. Bull. 93:1983;441-456.
35. Mountjoy C.Q., Rossor M.N., Iversen L.L., Roth M. Correlation of cortical cholinergic and GABA deficit with quantitative neuropathological findings in senile dementia. Brain. 107:1984;507-518.
36. 1-42-amyloid peptide. Brain Res. 912:2001;128-136.
37. Nava F., Carta G., Battasi A.M., Gessa G.L. D2 dopamine receptor enables delta-9-tetrahydrocannabinol induced memory impairment and reduction of hippocampal extracellular acetylcholine concentration. Br. J. Pharmacol. 131:2000;1201-1210.
38. Nitta A., Itoh A., Hasegawa T., Nabshima T. β-Amyloid protein induced Alzheimer's disease animal model. Neurosci. Lett. 170:1994;63-66.
39. Nitta A., Fukuta T., Hasegawa T., Nabshima T. Continuous infusion of β-amyloid protein into cerebral ventricle induces learning impairment and neuronal and morphological degeneration. Jpn. J. Pharmacol. 73:1997;51-57.
40. Perry E., Walker M., Grace J., Perry R. Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci. 22:1998;273-280.
41. Pertwee R.G. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol. Ther. 74:1997;129-180.
42. Pertwee R.G., Ross R.A. Cannabioid receptors and their ligands. Prostaglandins Leukot. Essent. Fat. Acids. 66:2002;101-121.
43. Podlisny M.B., Stephenson D.T., Frosch M.P., Tolan D.R., Lieberburg I., Clemens J.A., Selkoe D.J. Microinjection of synthetic amyloid β-protein in monkey cerebral cortex fails to produce acute neurotoxicity. Am. J. Pathol. 142:1993;17-24.
44. Reibaud M., Obinu M.C., Ledent C., Parmentier M., Bohme G.A., Imperato A. Enhancement of memory in cannabinoid receptor CB1, receptor knock-out mice. Eur. J. Pharmacol. 379:1999;R1-R2.
45. Terranova J.P., Storme J.J., Lafon N., Perio A., Rinaldi-Carmona M., Le Fur G., Soubrie P. Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR141716A. Psychopharmacology. 126:1996;165-172.
46. Venault P., Chapouthier G., de Carvalho L.P., Simiand J., Morre M., Dodd R.H., Rossier J. Benzodiazepine impairs and beta-carboline enhances performance in learning and memory tasks. Nature. 321:1986;864-866.
47. Vizi E.S., Kiss J.P. Neurochemistry and pharmacology of the major hippocampal transmitter systems: synaptic and non-synaptic interactions. Hippocampus. 8:1998;566-607.
48. Wang H., Chou C., Liao J., Chen C. Dehydroevodiamine attenuates β-amyloid peptide-induced amnesia in mice. Eur. J. Pharmacol. 413:2001;221-225.
49. Whitehouse P.J., Price D.L., Clarke A.W., Coyle J.T., DeLong M.R. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann. Neurol. 10:1981;122-126.
50. Winkler J., Conoer D.J., Frautschy S.A., Behl C., White J.J., Cole G.M., Thal L.J. Lack of long-term effects after β-amyloid protein injections in rat brain. Neurobiol. Aging. 15:1994;601-607.
51. Yamada K., Tanaka T., Sensaki K., Kameyama T., Nabeshima T. Propentofylline improves learning and memory deficits in rats induced by β-amyloid protein-(1-40). Eur. J. Pharmacol. 349:1998;15-22.
52. Yamada K., Tanaka T., Han D., Senzaki K., Kameyama T. Protective effects of idebenone and α-tocopherol on β-amyloid-(1-42)-induced learning and memory deficits in rats: implication of oxidative stress in β-amyloid-induced neurotoxicity in vivo. Eur. J. Neurosci. 11:1999;83-90.
53. Yamamoto T., Hirano A. Nucleus raphe dorsalis in Alzheimer's disease: neurofibrillary tangles and loss of large neurons. Ann. Neurol. 17:1985;573-577.
54. Yan J.J., Cho J.Y., Kim H.S., Kim K.L., Jung J.S., Huh S.O., Suh H.W., Kim Y.H., Song D.K. Protection against β-amyloid peptide toxicity in vivo with long-term administration of ferulic acid. Br. J. Pharmacol. 133:2001;89-96.